Alaunos Therapeutics, Inc.
TCRT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 100% | -99.8% | 634.2% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 100% | -95,960% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -46,770% | -618,080% | -1,088.9% | -18,835.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -46,790% | -702,800% | -1,291.2% | -19,786.7% |
| EPS Diluted | -2.92 | -21.97 | -25.97 | -53.8 |
| % Growth | 86.7% | 15.4% | 51.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |